No ratings

Welcome to the weekend everybody! You know, it's been a couple of days since we've had a chance to take a step back and just look at the broad market - we wanted to focus on RepliCel Life Sciences (REPCF, CVE:RP) in Wednesday's edition, and on Thursday morning we needed to tell you the complete story for Taranis Resources Inc. (TNREF, CVE:TRO). We'll make up for little lost time today by taking an extra-diligent look at where stocks are as a whole, and where they're likely to go next.

It's also in today's edition we want to go ahead and take a look at the S&P 500's earnings trajectory.... past and projected. We gave you (and even showed you) a detailed breakdown of the market's earnings through last week in Tuesday's edition of the newsletter. But, what we didn't give you then was the overarching view. We'll do that below.

First, however, we want to take a quick look at a curious move dished out today by Featured Stock Staffing 360 Solutions (STAF). The market is dropping a hint it may be wise to take.

No ratings

Good morning friends and fellow traders. As we promised you in Tuesday afternoon's newsletter, we've got a new trading idea for you today... a biotech we think you're going to like.

Whether veteran traders know they know it or not, there's a sweet spot for biopharma stocks. The period between when data for clinical trials starts to get reported in earnest and the beginning of full-blown commercialization -- when much of the risk a company faces starts to evaporate -- can be especially bullish for a biotech or biopharma name. Think of it as the point in time when you see a light start to shine at the end of the tunnel, and you know it's not an oncoming train. It's a very exciting stage for a company, and its shareholders.

That's where RepliCel Life Sciences (REPCF, CVE:RP) is in its life right now. This year looks like it's going to be a really fun year for the company. Ditto for REPCF shareholders (or RP shareholders, if you're in Canada). The data from a couple of key trials is due this quarter, which should set the stage for more developmental news all throughout this year.

No ratings

Happy Valentine's Day, one and all. If you haven't yet gotten your sweetheart that special something, well, good luck with that - it's pretty late in the game to start now (though not impossible).

Everyone have a great evening if you're going out on a date. As for me, my wife and I are more than content to stay in and avoid the crowds.

Before you get too distracted by the day's usual events, however, let's spend a couple minutes taking care of some business, shall we? We've got that earnings season update for you we've been talking about for a while. We'll get to it in a moment. Here's a teaser though... there's even less reason for stocks to be priced where they are now versus what we thought just a few days ago.

No ratings

Welcome back from the weekend, everybody. We've got quite a bit to get through today, so let's just take it from the top and let you know Radient Technologies (RDDTF, RTI.V) shares soared more than 20% today on the heels of news that it's going to raise $6 million at a very palatable price. And, none other than Aurora Cannabis (ACB.V) was chipping in as much as $1.2 million to become not just a partner, but an investor.

The name should ring a bell. Aurora Cannabis is the company that first expressed interest in Radient Technologies' capabilities as an extractor of cannabis oils a couple of months ago. Aurora didn't make a firm commitment to Radient at the time, wanting to further explore the company's capabilities before digging in. Apparently it's become convinced in the meantime. Aurora Cannabis is willing to buy a pretty big piece of the offering at a price of $0.45 per share. The deal also offers warrants to buy more RTI shares at $0.70 down the road, which the stock (the Canadian shares, not the US-listed OTC shares) just eclipsed today.

What's so interesting is what this likely means. Although Aurora and Radient have both been talking around a potential partnership for a couple of months now, neither has confirmed any kind of deal has been inked. However, with Aurora putting its money where its mouth is, so to speak, clearly there's something the company has a lot of faith in. Maybe there's some sort of exclusivity? We'll see. Just sayin', sometimes you have to read between the lines.

No ratings

Good Friday All. It's been about a week since my last Elite Opportunity update, and for those of you who are serious about making money in the markets, today's update could be extremely important.